Abstract
Contraception is an important issue for women with diabetes mellitus as unplanned pregnancy can present major maternal and perinatal complications. The rising incidence of diabetes worldwide means increasing thought needs to be given to contraceptive options for these women. This article reviews current evidence and recommends best practice for prescribing hormonal contraceptives in women with diabetes.
Women with diabetes have the same choice of contraceptives as the general population, but the potential metabolic effects of hormonal methods need to be considered in relation to an individual’s diabetic profile and their need for effective contraception. Currently, there appear to be wide variations in the way that professionals evaluate the risk-benefit equation, and significant differences in prescribing practice have been identified. The World Health Organization (WHO) has established medical eligibility criteria to assist in assessing such risks.
Cardiovascular disease is a major concern, and for women with diabetes who have macrovascular or microvascular complications, nonhormonal methods are recommended. Studies of young women with diabetes and no vascular changes who are taking low-dose combined oral contraceptives (COCs) have been reassuring, although larger long-term studies are needed. There is little evidence that any changes in glycemic control caused by COCs are of clinical relevance. While low-dose COCs appear to cause minimal change in the lipid profile and may even be beneficial in this respect, there are some concerns in relation to progestogen only pills and injectable contraceptives in certain women.
There is little evidence of best practice for the follow-up of women with diabetes prescribed hormonal contraception. It is generally agreed that blood pressure, weight, and body mass index measurements should be ascertained, and blood glucose levels and baseline lipid profiles assessed as relevant. Research on hormonal contraception has been carried out in healthy populations; more studies are needed in women with diabetes and women who have increased risks of cardiovascular disease.
Similar content being viewed by others
Notes
The use of the registered name is for identification purposes only and does not imply endorsement.
References
WHO Study Group on Prevention of Diabetes Mellitus Prevention of diabetes mellitus: report of a WHO study group. WHO Technical Report Series 844. Geneva: WHO, 1994
Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14: S7–S85
WHO. Improving access to quality care in Family Planning medical eligibility criteria for contraceptive use. WHO 2000 [online]. Available from URL: http://www.who.int/reproductive-health/publications [Accessed 2002 Oct 16]
ONS. Key Health Statistics from General Practice 1998. London: ONS, 2000
ACOG Committee on Practice Bulletins — Gynecology. ACOG practice bulletin: the use of hormonal contraception in women with coexisting medical conditions. Int J Gynaecol Obstet 2001; 75(1): 93–106
Betschart J. Oral contraception and adolescent women with insulin-dependent diabetes mellitus: risks, benefits, and implications for practice. Diabetes Educ 1996; 22(4): 374–8
Girling J, de Swiet M, Hope C. Contraception for women with diabetes or hypertension. Trends Urol Gynaecol Sexual Health 1997 Nov/Dec; 2(8): 23–34
Mills J, Knowpp R, Simpson J. Lack or relation of increased malformation rates in infants of diabetic mothers to glycaemic control during organogenesis. N Engl J Med 1988; 318: 671–6
Mestman JH, Schmidt Sarosi C. Diabetes mellitus and fertility control: contraception management issues. Am J Obstet Gynecol 1993; 168: 2012–20
Kjaer K, Hagen C, Sando SH, et al. Contraception in women with IDDM: an epidemiological study. Diabetes Care 1992; 15: 1585–90
Hollingworth BA. Contraception and medical disorders. In: Kubba A, Sanfillippo J, Hampton N, editors. Contraception and office gynaecology. London: WB Saunders, 1999: 193–208
Klein BEK, Klein R, Moss SE. Exogenous estrogen exposures and changes in diabetic retinopathy. Diabetes Care 1999; 22(12): 1984–7
Laing SP, Swerdlow AJ, Slater SD, et al. The British Diabetic Association Cohort Study, 11: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999; 16(6): 466–71
Swerdlow AJ, Jones ME. Mortality during 25 years of follow-up of a cohort with diabetes. Int J Epidemiol 1996; 25: 1250–61
Fontbonne A, Basdevant A, Faguer B, et al. Contraceptive practice in 209 diabetic women regularly attending a specialized diabetes clinic. Diabete Metab 1987; 13(4): 411–6
Kimmerle R, Schmitt G, Berger M. Contraception in patients with type I diabetes: a survey of 808 women of reproductive age. Geburtshilfe Frauenheilkd 1994; 54(12): 691–6
International Planned Parenthood Federation (PPF). Directory of hormonal contraceptives [online]. Available from URL: http://www.contraceptive.ippf.org [Accessed 2003 Jan 7]
Crook D. Do different brands of oral contraception differ in their effects on cardiovascular disease? Br J Obstet Gynaecol 1997; 104: 516–20
Porcile A, Gallardo E. Long term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives. Fertil Steril 1991; 55: 877–81
Parsey KS, Pong A. An open label multicenter study to evaluate Yasmin, a low dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000; 61(2): 105–11
British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF) 2003 Mar; 45
Wingrave SJ, Kay CR, Vessey MP. Oral contraceptives & diabetes mellitus. BMJ 1979; 1(6155): 23
Kjos SL, Peters RK, Xiang A, et al. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 1998; 280(6): 533–8
Kim C, Scidel KW, Begier EA, et al. Diabetes and depot medroxyprogesterone contraception in Navajo women. Arch Intern Med 2001; 161(14): 1766–71
Chasan-Taber L, Willett WC, Stampfer MJ, et al. A prospective study of oral contraceptives and NIDDM among US women. Diabetes Care 1997; 20(3): 330–5
Kim C, Siscovick DS, Sidney S, et al. Oral contraceptive use and association with glucose, insulin, and diabetes in young adult women: the CARDIA study. Diabetes Care 2002; 25(6): 1027–32
Lawrenson RA, Leydon GM, Williams TJ, et al. Patterns of contraception in UK women with Type 1 diabetes: a GP database study. Diabet Med 1999; 16: 395–9
Gibb D, Hockey S, Brown LJ, et al. Attitudes and knowledge regarding contraception and pre-pregnancy counseling in insulin dependent diabetes. N Z Med J 1994; 107: 484–6
RCOG. Royal College of General Practitioners oral contraceptive study. Lancet 1977; II: 727–31
Vessey MP, McPherson K, Johnson B. Mortality among women participating in the Oxford Family Planning Association Contraceptive Study. Lancet 1977; II: 731–7
Jensen G, Nyboe J, Appleyard M, et al. Risk factors for acute myocardial infarction in Copenhagen: II. smoking, alcohol intake, physical activity, obesity, oral contraception, diabetes, lipids, and blood pressure. Eur Heart J 1991; 12(3): 298–308
Sidney S, Siscovick DS, Petitti DB, et al. Myocardial infarction & use of low-dose oral contraceptives, a pooled analysis of 2 US studies. Circulation 1998; 98: 1058–63
Farley TM, Collins J, Schlesselman JJ. Hormonal contraception and risk of cardiovascular disease: an international perspective. Contraception 1998; 57(3): 211–30
Lidegaard O. Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. Br J Obstet Gynaecol 1995; 102(2): 153–9
Mammen EF. Oral contraceptives and blood coagulation: a critical review. Am J Obstet Gynecol 1982 Mar 15; 142 (6 Pt 2): 781–90
Petersen KR, Skouby SO, Sidelmann J, et al. Effects of contraceptive steroids on cardiovascular risk factors in women with insulin-dependent diabetes mellitus. Am J Obstet Gynecol 1994; 171: 400–5
Diab KM, Zaki MM. Contraception in diabetic women: comparative metabolic study of Norplant, depot medroxyprogesterone acetate, low dose oral contraceptive pill and CuT380A. J Obstet Gynaecol Res 2000; 26(1): 17–26
Sorensen MB, Collins P, Ong PJL, et al. Long term use of contraceptive Depot medroxyprogesterone Acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation 2002; 106(13): 1646–51
Monster TB, Janssen WM, de Jong PE, et al. Prevention of Renal and Vascular End Stage Disease Study Group. Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med 2001; 161(16): 2000–5
Garg SK, Chase P, Marshall G, et al. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. JAMA 1994; 271(14): 1099–102
Kirwan JF, Tsaloumas H, Prior P, et al. Sex hormone preparations and retinal vein occlusion. Eye 1997; 11(1): 53–6
Amiel SA, Caprio S, Sherwin RS, et al. Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab 1991; 72: 277–82
Polderman KH, Gooren LJG, Asscheman H, et al. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 1994; 79: 265–71
Anderson B, Mattson L-A, Hahn L, et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 638–43
Darko DA, Dornhorst A, Kennedy G, et al. Glycaemic control and plasma lipoproteins in menopausal women with type 2 diabetes treated with oral and transdermal combined hormone replacement therapy. Diabet Res Clin Pract 2001; 54(3): 157–64
Livingstone C, Collison M. Sex steroids and insulin resistance. Clin Sci (Lond) 2002; 102(2): 151–66
Skouby SO, Molsted-Pedersen L, Petersen KR. Contraception for women with diabetes: an update. Baillieres Clin Obstet Gynaecol 1991; 5: 493–503
Blum M, Rusecky Y, Gelernter I. Glycohemoglobin (Hb A1) levels in oral contraceptive users. Eur J Obstet Gynecol Reprod Biol 1983; 15(2): 97–101
Steel JM, Duncan LJ. Contraception for the insulin-dependent diabetic woman: the view from one clinic. Diabetes Care 1980; 3(4): 557–60
Radberg T, Gustafson A, Skryten A, et al. Oral contraception in diabetic women: a cross-over study on serum and HDL lipids and diabetes control during progestogen and combined estrogen/progestogen contraception. Horm Metab Res 1982; 14(2): 61–5
Skouby SO, Molsted-Pedersen L, Kuhl C. Low dosage oral contraception in women with previous gestational diabetes. Obstet Gynecol 1982; 59(3): 325–8
Godsland IF. Interaction of oral contraceptive use with the effects of age, exercise habits and other cardiovascular risk modifiers on metabolic risk markers. Contraception 1996; 53(1): 9–16
Klein B, Moss SE, Klein R. Oral contraceptives in women with diabetes. Diabetes Care 1990; 13(8): 1585–90
Kjaer K, Hagen C, Sando S, et al. Contraception in women with IDDM. Diabetes Care 1992; 15(11): 1585–90
Petersen KR, Skouby SO, Vedel P, et al. Hormonal contraception in women with IDDM. Diabetes Care 1995; 18(6): 800–6
Dorflinger LJ. Metabolic effects of implantable steroid contraceptives for women. Contraception 2002; 65(1): 47–62
Geurts TBP, Goorissen EM, Sitsen JMA. Summary of drug interactions with oral contraceptives. Carnforth: The Parthenon Publishing Group, 1993
Steel JM. Pregnancy counseling and contraception in the insulin-dependent diabetic patient. Clin Obstet Gynaecol 1985; 28(3): 553–66
Selby PL, Oakley CE. Women’s problems and diabetes. Diabet Med 1992; 9(3): 290–2
World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case control study. Lancet 1995; 346: 1575–82
Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet 1995; 346: 1589–93
Spitzer WO, Lewis MA, Heinemann LA, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312: 83–8
Farmer RD, Lawrenson RA, Todd JC, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 2000; 49(6): 580–90
Lewis MA, MacRae KD, Kuhl-Habichl D, et al. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999; 14(6): 1493–9
Mr Justice MacKay. XYZ and others & Schering Healthcare Ltd, Organon Laboratories Ltd and John Wyeth and Brother Ltd. High Court of Justice, Queens Bench Division, London. 29th July 2002, EWHC 1420 (QB)
RCOG Faculty of Family Planning & Reproductive Health Care. First prescription of combined oral contraception: recommendations for clinical practice. Br J Fam Planning 2000; 26(1): 27–38
Manolopoulos K, Kiess W, Braems GA, et al. Which contraceptive methods are recommended for young women with type 1 diabetes mellitus? A survey among gynaecologists in Greece. Eur J Obstet Gynaecol Reprod Biol 2001; 99(2): 232–7
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shawe, J., Lawrenson, R. Hormonal Contraception in Women with Diabetes Mellitus. Mol Diag Ther 2, 321–330 (2003). https://doi.org/10.2165/00024677-200302050-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00024677-200302050-00004